Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 280 participants.

Also called NCT03764241

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 280 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03764241
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03764241. Randomized; no masking; primary purpose treatment. Start 2020-02-01 (actual); primary completion 2022-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
Acronym
EARLYmyo-LVT
Condition
ST Segment Elevation Myocardial Infarction
Condition
Left Ventricular Thrombus
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Vitamin K Antagonist
Lead sponsor
RenJi Hospital (class: other)
Collaborator
Shanghai 6th People's Hospital (class: other)
Collaborator
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (class: other)
Collaborator
Shanghai Minhang Central Hospital (class: other)
Collaborator
Shanghai Songjiang Central Hospital (class: not stated)
Collaborator
Shanghai Fengxian District Central Hospital (class: other)
Collaborator
Zhoushan Hospital in Zhejiang Province (class: not stated)

Record details

Record id
cardio:ct-nct03764241
Content hash
227d5464449c6cab65af0d5a2f5e9c8ce428be92b3b7fe71a6ce5b8b9c29ec26